FDA awards Novartis expanded approval for breast cancer therapy
Posted:
Kisqali, a key targeted therapy for breast cancer from Novartis, until now has been indicated only for patients with metastatic disease. But, the Food and Drug Administration approved Kisqali in combination with hormone therapy for patients with certain early-stage breast cancers.
A machine learning algorithm developed by Cambridge scientists was able to correctly identify in 97 cases out of 100 whether or not an individual had coeliac disease based on their biopsy, new research has shown.
Read more here.
Leveraging the power of AI and machine learning technologies, researchers at Weill Cornell Medicine developed a more effective model for predicting how patients with muscle-invasive bladder cancer will respond to chemotherapy.
Read more here.
Attendees
Sponsors and
Exhibitors
AI In Healthcare: A Virtual Course
Contact us